​

Apellis Pharmaceuticals (APLS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Apellis Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$709.95M

Latest Revenue (Q)

$171.39M

Main Segment (Y)

Product

Apellis Pharmaceuticals Revenue by Period

Apellis Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$709.95M79.01%
2023-12-31$396.59M425.83%
2022-12-31$75.42M13.31%
2021-12-31$66.56M-73.44%
2020-12-31$250.65M100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Apellis Pharmaceuticals generated $709.95M in revenue during NA 2024, up 79.01% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Apellis Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-06-30$171.39M2.75%
2025-03-31$166.80M-21.52%
2024-12-31$212.53M7.98%
2024-09-30$196.83M-1.43%
2024-06-30$199.69M15.88%
2024-03-31$172.32M17.73%
2023-12-31$146.38M32.59%
2023-09-30$110.40M16.25%
2023-06-30$94.97M111.77%
2023-03-31$44.85M97.88%
2022-12-31$22.66M2.75%
2022-09-30$22.06M35.13%
2022-06-30$16.32M13.50%
2022-03-31$14.38M-76.15%
2021-12-31$60.29M967.08%
2021-09-30$5.65M806.90%
2021-06-30$623.00K100.00%
2021-03-31--100.00%
2020-12-31$250.00M38599.69%
2020-09-30$646.00K100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$-142.00K100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$11.54K100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--100.00%
2017-12-31$11.54K100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2014-12-31-100.00%
2014-09-30--

Apellis Pharmaceuticals generated $171.39M in revenue during Q2 2025, up 2.75% compared to the previous quarter, and up 99.46% compared to the same period a year ago.

Apellis Pharmaceuticals Revenue Breakdown

Apellis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Licensing And Other Revenue$71.41M$30.31M$10.33M$51.42M-
Product$709.95M$366.28M$65.09M$15.15M-
Collaboration----$152.00K

Apellis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (90.86%), and Licensing And Other Revenue (9.14%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Product$171.39M$149.90M$191.17M$176.57M$179.14M$163.07M$138.65M$99.18M$89.64M$38.80M$19.65M$17.68M$15.65M$12.11M$9.21M$5.31M
Licensing And Other Revenue$7.11M$16.90M$21.36M$20.26M$20.55M$9.25M$7.72M$11.22M$5.32M$6.05M$3.01M$4.38M$668.00K$2.27M$51.08M$336.00K

Apellis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product (96.02%), and Licensing And Other Revenue (3.98%).

Apellis Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
APLSApellis Pharmaceuticals$709.95M$171.39M
RAREUltragenyx Pharmaceutical$560.23M$166.50M
LEGNLegend Biotech$285.14M$93.99M
TARSTarsus Pharmaceuticals$182.95M$78.33M
CDTXCidara Therapeutics$1.27M-
XENEXenon Pharmaceuticals-$7.50M
IMVTImmunovant--
APGEApogee Therapeutics--
CNTACentessa Pharmaceuticals-$15.00M
MLYSMineralys Therapeutics--
SRRKScholar Rock--

APLS Revenue FAQ

What is Apellis Pharmaceuticals’s yearly revenue?

Apellis Pharmaceuticals's yearly revenue for 2024 was $709.95M, representing an increase of 79.01% compared to 2023. The company's yearly revenue for 2023 was $396.59M, representing an increase of 425.83% compared to 2022. APLS's yearly revenue for 2022 was $75.42M, representing an increase of 13.31% compared to 2021.

What is Apellis Pharmaceuticals’s quarterly revenue?

Apellis Pharmaceuticals's quarterly revenue for Q2 2025 was $171.39M, a 2.75% increase from the previous quarter (Q1 2025), and a -14.17% decrease year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $166.8M, a -21.52% decrease from the previous quarter (Q4 2024), and a -3.21% decrease year-over-year (Q1 2024). APLS's quarterly revenue for Q4 2024 was $212.53M, a 7.98% increase from the previous quarter (Q3 2024), and a 45.19% increase year-over-year (Q4 2023).

What is Apellis Pharmaceuticals’s revenue growth rate?

Apellis Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 841.31%, and for the last 5 years (2020-2024) was 183.25%.

What are Apellis Pharmaceuticals’s revenue streams?

Apellis Pharmaceuticals's revenue streams in c 24 are Licensing And Other Revenue, and Product. Licensing And Other Revenue generated $71.41M in revenue, accounting 9.14% of the company's total revenue, up 135.61% year-over-year. Product generated $709.95M in revenue, accounting 90.86% of the company's total revenue, up 93.83% year-over-year.

What is Apellis Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Apellis Pharmaceuticals was Product. This segment made a revenue of $709.95M, representing 90.86% of the company's total revenue.